NeoGenomics/$NEO
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About NeoGenomics
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Ticker
$NEO
Sector
Primary listing
Industry
Health Care Providers & Services
Headquarters
Employees
2,200
ISIN
US64049M2098
Website
NeoGenomics Metrics
BasicAdvanced
$921M
-
-$0.61
1.64
-
Price and volume
Market cap
$921M
Beta
1.64
52-week high
$19.12
52-week low
$6.08
Average daily volume
2M
Financial strength
Current ratio
2.052
Quick ratio
1.821
Long term debt to equity
45.096
Total debt to equity
68.085
Interest coverage (TTM)
-10.89%
Profitability
EBITDA (TTM)
0.657
Gross margin (TTM)
44.30%
Net profit margin (TTM)
-11.54%
Operating margin (TTM)
-10.61%
Effective tax rate (TTM)
1.35%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-2.75%
Return on equity (TTM)
-8.57%
Valuation
Price to revenue (TTM)
1.352
Price to book
1.03
Price to tangible book (TTM)
26.88
Price to free cash flow (TTM)
-28.09
Free cash flow yield (TTM)
-3.56%
Free cash flow per share (TTM)
-25.49%
Growth
Revenue change (TTM)
10.10%
Earnings per share change (TTM)
-8.76%
3-year revenue growth (CAGR)
11.43%
10-year revenue growth (CAGR)
22.02%
3-year earnings per share growth (CAGR)
27.67%
10-year earnings per share growth (CAGR)
62.42%
What the Analysts think about NeoGenomics
Analyst ratings (Buy, Hold, Sell) for NeoGenomics stock.
Bulls say / Bears say
NeoGenomics achieved eight consecutive quarters of double-digit revenue growth under CEO Chris Smith's leadership, indicating strong operational performance. (ft.com)
The company reported a 10.6% year-over-year increase in revenue to $172 million in the quarter ended December 31, 2024, surpassing analyst expectations. (tradingview.com)
Analysts maintain a 'Moderate Buy' consensus rating with an average price target of $14.50, suggesting potential upside from current levels. (marketbeat.com)
The abrupt announcement of CEO Chris Smith's retirement effective April 1, 2025, led to a significant stock sell-off, reflecting investor concerns about leadership stability. (webull.com)
NeoGenomics reported a quarterly loss of $15.32 million for the quarter ended December 31, 2024, highlighting ongoing profitability challenges. (tradingview.com)
The company's operating margin has averaged negative 18.6% over the last five years, raising concerns about its path to profitability. (finviz.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jun 2025.
NeoGenomics Financial Performance
Revenues and expenses
NeoGenomics Earnings Performance
Company profitability
NeoGenomics News
AllArticlesVideos
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
Business Wire·3 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
GlobeNewsWire·4 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for NeoGenomics stock?
NeoGenomics (NEO) has a market cap of $921M as of June 27, 2025.
What is the P/E ratio for NeoGenomics stock?
The price to earnings (P/E) ratio for NeoGenomics (NEO) stock is 0 as of June 27, 2025.
Does NeoGenomics stock pay dividends?
No, NeoGenomics (NEO) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next NeoGenomics dividend payment date?
NeoGenomics (NEO) stock does not pay dividends to its shareholders.
What is the beta indicator for NeoGenomics?
NeoGenomics (NEO) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.